Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia

NCT05863234 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Aggressive NK Cell Leukemia

Interventions

DRUG: PPMX-T003

Sponsor

Hiroshima University Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]